408 related articles for article (PubMed ID: 35712773)
21. A Visible Codelivery Nanovaccine of Antigen and Adjuvant with Self-Carrier for Cancer Immunotherapy.
Dong X; Liang J; Yang A; Qian Z; Kong D; Lv F
ACS Appl Mater Interfaces; 2019 Feb; 11(5):4876-4888. PubMed ID: 30628437
[TBL] [Abstract][Full Text] [Related]
22. Nanovaccine that activates the NLRP3 inflammasome enhances tumor specific activation of anti-cancer immunity.
Manna S; Maiti S; Shen J; Weiss A; Mulder E; Du W; Esser-Kahn AP
Biomaterials; 2023 May; 296():122062. PubMed ID: 36863071
[TBL] [Abstract][Full Text] [Related]
23. STING agonist-loaded mesoporous manganese-silica nanoparticles for vaccine applications.
Xu C; Dobson HE; Yu M; Gong W; Sun X; Park KS; Kennedy A; Zhou X; Xu J; Xu Y; Tai AW; Lei YL; Moon JJ
J Control Release; 2023 May; 357():84-93. PubMed ID: 36948420
[TBL] [Abstract][Full Text] [Related]
24. Programming peptide-oligonucleotide nano-assembly for engineering of neoantigen vaccine with potent immunogenicity.
Xiang Z; Lu J; Rao S; Fu C; Yao Y; Yi Y; Ming Y; Sun W; Guo W; Chen X
Theranostics; 2024; 14(6):2290-2303. PubMed ID: 38646651
[No Abstract] [Full Text] [Related]
25. Biodegradable STING agonist nanoparticles for enhanced cancer immunotherapy.
Wilson DR; Sen R; Sunshine JC; Pardoll DM; Green JJ; Kim YJ
Nanomedicine; 2018 Feb; 14(2):237-246. PubMed ID: 29127039
[TBL] [Abstract][Full Text] [Related]
26. Lymph node-targeting nanovaccines for cancer immunotherapy.
Wang Q; Wang Z; Sun X; Jiang Q; Sun B; He Z; Zhang S; Luo C; Sun J
J Control Release; 2022 Nov; 351():102-122. PubMed ID: 36115556
[TBL] [Abstract][Full Text] [Related]
27. Nanovaccines for cancer immunotherapy: Focusing on complex formation between adjuvant and antigen.
Hashemi Goradel N; Nemati M; Bakhshandeh A; Arashkia A; Negahdari B
Int Immunopharmacol; 2023 Apr; 117():109887. PubMed ID: 36841155
[TBL] [Abstract][Full Text] [Related]
28. Dual-Targeted Self-Adjuvant Heterocyclic Lipidoid@Polyester Hybrid Nanovaccines for Boosting Cancer Immunotherapy.
Liu Z; Liu B; Feng Y; Zhao L; Wang Q; He H; Yin T; Zhang Y; Yang L; Gou J; Tang X
ACS Nano; 2024 Jun; 18(24):15557-15575. PubMed ID: 38837909
[TBL] [Abstract][Full Text] [Related]
29. Efficient Nanovaccine Delivery in Cancer Immunotherapy.
Zhu G; Zhang F; Ni Q; Niu G; Chen X
ACS Nano; 2017 Mar; 11(3):2387-2392. PubMed ID: 28277646
[TBL] [Abstract][Full Text] [Related]
30. A bi-adjuvant nanovaccine that potentiates immunogenicity of neoantigen for combination immunotherapy of colorectal cancer.
Ni Q; Zhang F; Liu Y; Wang Z; Yu G; Liang B; Niu G; Su T; Zhu G; Lu G; Zhang L; Chen X
Sci Adv; 2020 Mar; 6(12):eaaw6071. PubMed ID: 32206706
[TBL] [Abstract][Full Text] [Related]
31. Lymph node-targeted neoantigen nanovaccines potentiate anti-tumor immune responses of post-surgical melanoma.
Chu Y; Qian L; Ke Y; Feng X; Chen X; Liu F; Yu L; Zhang L; Tao Y; Xu R; Wei J; Liu B; Liu Q
J Nanobiotechnology; 2022 Apr; 20(1):190. PubMed ID: 35418151
[TBL] [Abstract][Full Text] [Related]
32. Expanding the Potential of Neoantigen Vaccines: Harnessing Bacille Calmette-Guérin Cell-Wall-Based Nanoscale Adjuvants for Enhanced Cancer Immunotherapy.
Liu K; Peng J; Guo Y; Li Y; Qi X; Duan D; Li T; Li J; Niu Y; Han G; Zhao Y
ACS Nano; 2024 May; 18(18):11910-11920. PubMed ID: 38680054
[TBL] [Abstract][Full Text] [Related]
33. Engineered Nanoparticles for Cancer Vaccination and Immunotherapy.
Aikins ME; Xu C; Moon JJ
Acc Chem Res; 2020 Oct; 53(10):2094-2105. PubMed ID: 33017150
[TBL] [Abstract][Full Text] [Related]
34. Modularly Programmable Nanoparticle Vaccine Based on Polyethyleneimine for Personalized Cancer Immunotherapy.
Nam J; Son S; Park KS; Moon JJ
Adv Sci (Weinh); 2021 Mar; 8(5):2002577. PubMed ID: 33717838
[TBL] [Abstract][Full Text] [Related]
35. Neoantigen-Based Nanovaccine In Combination with Immune Checkpoint Inhibitors Abolish Postsurgical Tumor Recurrence and Metastasis.
Zheng P; He J; Yang Z; Fu Y; Yang Y; Li W; Ding Y; Yang X; Ma Y
Small; 2023 Dec; 19(50):e2302922. PubMed ID: 37649222
[TBL] [Abstract][Full Text] [Related]
36. Vaccination of TLR7/8 Agonist-Conjugated Antigen Nanoparticles for Cancer Immunotherapy.
Wang N; Zhang G; Zhang P; Zhao K; Tian Y; Cui J
Adv Healthc Mater; 2023 Sep; 12(22):e2300249. PubMed ID: 37016572
[TBL] [Abstract][Full Text] [Related]
37. Nanovaccines for cancer immunotherapy.
Zhang Y; Lin S; Wang XY; Zhu G
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2019 Sep; 11(5):e1559. PubMed ID: 31172659
[TBL] [Abstract][Full Text] [Related]
38. Minimalist Nanovaccine with Optimized Amphiphilic Copolymers for Cancer Immunotherapy.
Niu L; Miao Y; Cao Z; Wei T; Zhu J; Li M; Bai B; Chen L; Liu N; Pan F; Zhu J; Wang C; Yang Y; Chen Q
ACS Nano; 2024 Jan; 18(4):3349-3361. PubMed ID: 38230639
[TBL] [Abstract][Full Text] [Related]
39. Nanovaccine biomineralization for cancer immunotherapy: a NADPH oxidase-inspired strategy for improving antigen cross-presentation via lipid peroxidation.
Su R; Chong G; Dong H; Gu J; Zang J; He R; Sun J; Zhang T; Zhao Y; Zheng X; Yang Y; Li Y; Li Y
Biomaterials; 2021 Oct; 277():121089. PubMed ID: 34481292
[TBL] [Abstract][Full Text] [Related]
40. Personalized combination nano-immunotherapy for robust induction and tumor infiltration of CD8
Park KS; Nam J; Son S; Moon JJ
Biomaterials; 2021 Jul; 274():120844. PubMed ID: 33962217
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]